Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsBrandon Kitay, MD, PhD
Assistant Professor Adjunct, PsychiatryAbout
Research
Publications
2026
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial.
Wilkinson S, Kitay B, Macaluso M, Santucci M, Kumpf K, Voghell C, Astorino L, Hershenberg R, Martinez-Kaigi V, Nowell T, Thase M, Sanacora G, Rhee T. Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial. The Journal Of Clinical Psychiatry 2026, 87 PMID: 42095692, DOI: 10.4088/jcp.25m16285.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyBeck Scale for Suicide IdeationSuicidal ideationBehavioral therapyCourse of CBTColumbia-Suicide Severity Rating Scale scoresMontgomery-Asberg Depression Rating ScaleAdjunctive cognitive behavioral therapyScale for Suicide IdeationCognitive behavioral therapy groupDepression Rating ScaleTreatment-seeking patientsGlobal Improvement ScaleSuicide-related eventsDose of esketamineRating Scale scoresStudy completion ratesMontgomery-AsbergSuicide severityDepressive disorderMajor depressionRelapse preventionTAU groupEsketamineAttainment of skills523. Clinical Outcomes Following Transition From Intranasal Esketamine to Intravenous Racemic Ketamine in Treatment-Resistant Depression: A Retrospective Case Series
Hale M, Mandell A, Hershenberg R, Chatham A, Ma T, Riva-Posse P, Kitay B. 523. Clinical Outcomes Following Transition From Intranasal Esketamine to Intravenous Racemic Ketamine in Treatment-Resistant Depression: A Retrospective Case Series. Biological Psychiatry 2026, 99: s324. DOI: 10.1016/j.biopsych.2026.03.757.Peer-Reviewed Original ResearchNon-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol
Wilkinson S, Prashad S, Dalthorp R, Harding L, Kitay B, Parikh S, Dziura J, Clayton A, Fram G, Lepoutre V, Brown J, Ostroff R, Sanacora G. Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol. Contemporary Clinical Trials 2026, 164: 108273. PMID: 41780747, DOI: 10.1016/j.cct.2026.108273.Peer-Reviewed Original ResearchQuick Inventory of Depressive SymptomatologyTreatment-resistant depressionIntranasal esketamineInventory of Depressive SymptomatologyIV ketamineS-enantiomer of ketamineRapid-acting antidepressantsIN esketamineAnxious distressAnxiety severityDepression severityDepressive symptomatologyPsychiatric illnessEsketamineComparative effectiveness studiesWeeks of treatmentDepressionNon-inferiorityRemission rateKetamineFDA-approved therapiesNon-inferiority studyPatient-reported outcomesAdjunctive therapyClinical differences
2025
A Retrospective Analysis of the Impact of Electroconvulsive Therapy on Anxiety Symptoms in Patients With Treatment-Resistant Depression
Laszcz J, Wang C, Riva-Posse P, Kim J, Tsygankova V, Mandell A, Rice H, Hermida A, Kitay B, Crowell A, McDonald W, Hershenberg R. A Retrospective Analysis of the Impact of Electroconvulsive Therapy on Anxiety Symptoms in Patients With Treatment-Resistant Depression. Journal Of Ect 2025, 41: 250-256. PMID: 39853314, DOI: 10.1097/yct.0000000000001113.Peer-Reviewed Original ResearchTreatment-resistant depressionTreatment-resistant depressed patientsElectroconvulsive therapySymptoms of depressionSymptoms of anxietyAnxiety symptomsDepressive symptomsAcute course of ECTGeneralized Anxiety Disorder 7 scalePredictors of antidepressant responseImprovement of anxiety symptomsImpact of electroconvulsive therapyCourse of ECTImprove symptoms of anxietyHigher symptoms of anxietyBeck Depression Inventory IIAnxiety symptom severityNaturalistic outpatient settingAcute ECT courseHigher levels of anxietyElectroconvulsive therapy treatmentsLevels of anxietyTrajectory of improvementAntidepressant responseAnxious symptoms
2024
Lifetime history of childhood adversity and substance abuse in patients with treatment resistant depression
Giampetruzzi E, McDonald W, Rice H, Kitay B, Hermida A, Posse P, Hershenberg R. Lifetime history of childhood adversity and substance abuse in patients with treatment resistant depression. Personalized Medicine In Psychiatry 2024, 43: 100122. DOI: 10.1016/j.pmip.2024.100122.Peer-Reviewed Original ResearchTreatment-resistant depressionAdverse childhood experiencesHistory of substance abuseSubstance abuseDepressive disorderAssociated with treatment-resistant depressionTreatment-resistant depressed patientsPersistent depressive disorderLifetime substance abuseEffects of adverse childhood experiencesRisk of substance abuseAssociation of adverse childhood experiencesACE subtypesACE exposureResistant depressionLifetime historyChildhood adversityChildhood experiencesAbuseClinical samplesDepressionDisordersLogistic regression analysisMDDSubstancesChapter 19 Deep brain stimulation for depression
Kitay B, Riva-Posse P. Chapter 19 Deep brain stimulation for depression. 2024, 451-478. DOI: 10.1016/b978-0-443-18496-3.00019-7.ChaptersMajor depressive disorderTreatment-refractory depressionObsessive-compulsive disorderDeep brain stimulationBrain stimulationTarget of deep brain stimulationAntidepressant therapyDepressive disorderNeuropsychiatric disordersClinical psychiatryDepressionDisordersMovement disordersNetwork hypothesisPsychotherapyTherapeutic optionsSurgical interventionPsychiatryNeuromodulation technologyStimulationEpilepsyInterventionHypothesisTechnical advancesPharmacology
2019
The Successful Use of Electroconvulsive Therapy in a Patient With Cerebral Aneurysms and a Pituitary Lesion
Kitay BM, Katz RB, Wilkinson ST, Ostroff RB. The Successful Use of Electroconvulsive Therapy in a Patient With Cerebral Aneurysms and a Pituitary Lesion. Journal Of Ect 2019, 35: e4-e5. PMID: 29952859, PMCID: PMC6309946, DOI: 10.1097/yct.0000000000000516.Commentaries, Editorials and Letters
2018
50 Studies Every Psychiatrist Should Know
Chapter 18: Memantine in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil. Brandon M. Kitay and Rajesh R. Tampi; Chapter 29: Exposure and Ritual Prevention, Clomipramine, or Their Combination for Obsessive-Compulsive Disorder. Brandon M. Kitay and Michael H. BlochBooks
2013
Mislocalization of neuronal mitochondria reveals regulation of Wallerian degeneration and NMNAT/WLDS-mediated axon protection independent of axonal mitochondria
Kitay BM, McCormack R, Wang Y, Tsoulfas P, Zhai RG. Mislocalization of neuronal mitochondria reveals regulation of Wallerian degeneration and NMNAT/WLDS-mediated axon protection independent of axonal mitochondria. Human Molecular Genetics 2013, 22: 1601-1614. PMID: 23314018, PMCID: PMC3657477, DOI: 10.1093/hmg/ddt009.Peer-Reviewed Original ResearchConceptsDrosophila larval motor neuronsLarval motor neuronsAxonal mitochondriaRole of mitochondriaEvolutionary conservationMN axonsMorphological comparisonMotor neuronsMitochondriaMolecular pathwaysAxon protectionNeuronal mitochondriaWallerian degenerationNeurodegenerative diseasesCentral roleIntense investigationDistal axonsRegulationMorphological changesDorsal root ganglion explantsAxon degenerationHuman DRG neuronsCritical sitesUnderlying mechanismMislocalization
2010
Dealing with Misfolded Proteins: Examining the Neuroprotective Role of Molecular Chaperones in Neurodegeneration
Ali YO, Kitay BM, Zhai RG. Dealing with Misfolded Proteins: Examining the Neuroprotective Role of Molecular Chaperones in Neurodegeneration. Molecules 2010, 15: 6859-6887. PMID: 20938400, PMCID: PMC3133442, DOI: 10.3390/molecules15106859.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMolecular chaperonesMisfolded proteinsNormal protein homeostasisRepair of proteinsProtein-protein interactionsHuman neurodegenerative diseasesNeurodegenerative diseasesNascent proteinsProtein homeostasisNetwork of moleculesCellular functionsConformational diseasesProteolytic machineryProtein speciesCellular stressChaperonesClearance of proteinsNormal proteinProteinFunctional classificationSuch diseasesFoldingEnvironmental factorsWide arrayTherapeutic potential